The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: To study the possible association of founder mutations in the lysosomal storage disorder genes HEXA, SMPD1, and MCOLN1 (causing Tay-Sachs, Niemann-Pick A, and mucolipidosis type IV diseases, respectively) with Parkinson disease (PD).
Methods: Two PD patient cohorts of Ashkenazi Jewish (AJ) ancestry, that included a total of 938 patients, were studied: a cohort of 654 patients from Tel Aviv, and a replication cohort of 284 patients from New York. Eight AJ founder mutations in the HEXA, SMPD1, and MCOLN1 genes were analyzed. The frequencies of these mutations were compared to AJ control groups that included large published groups undergoing prenatal screening and 282 individuals matched for age and sex.
Results: Mutation frequencies were similar in the 2 groups of patients with PD. The SMPD1 p.L302P was strongly associated with a highly increased risk for PD (odds ratio 9.4, 95% confidence interval 3.9–22.8, p < 0.0001), as 9/938 patients with PD were carriers of this mutation compared to only 11/10,709 controls.
Conclusions: The SMPD1 p.L302P mutation is a novel risk factor for PD. Although it is rare on a population level, the identification of this mutation as a strong risk factor for PD may further elucidate PD pathogenesis and the role of lysosomal pathways in disease development.
GLOSSARY
- AJ=
- Ashkenazi Jewish;
- ANOVA=
- analysis of variance;
- CI=
- confidence interval;
- GCase=
- glucocerebrosidase;
- OR=
- odds ratio;
- PD=
- Parkinson disease;
- SMase=
- sphingomyelin phosphodiesterase
Footnotes
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Editorial, page 1544
Supplemental data at www.neurology.org
- Received July 20, 2012.
- Accepted in final form December 10, 2012.
- © 2013 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
- Re:The p.L302P mutation of lysosomal enzyme gene SMPD1 is rare in Taiwanese Parkinson's disease
- Avi Orr-Urtreger, Director, The Genetic Institute, Tel-Aviv Sourasky Medical Centeraviorr@tlvmc.gov.il
- Ziv Gan-Or, Tel-Aviv, Israel
Submitted July 18, 2013 - The p.L302P mutation of lysosomal enzyme gene SMPD1 is rare in Taiwanese Parkinson's disease
- Ruey-Meei Wu, Professor, Department of Neurology, National Taiwan University Hospitalrobinwu@ntu.edu.tw
- Chin-Hsien Lin, Han-I Lin, Ruey-Meei Wu; Taipei, Taiwan.
Submitted July 01, 2013
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Dennis Bourdette and Dr. Lindsey Wooliscroft
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Articles
Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onsetZ. Gan-Or, N. Giladi, U. Rozovski et al.Neurology, April 23, 2008 -
Editorial
Lysosomal enzyme defects and Parkinson diseaseNutan Sharma et al.Neurology, March 27, 2013 -
Article
Differential effects of severe vs mild GBA mutations on Parkinson diseaseZiv Gan-Or, Idan Amshalom, Laura L. Kilarski et al.Neurology, February 04, 2015 -
Clinical Implications of Neuroscience Research
The autophagy-lysosomal pathwayGeneral concepts and clinical implicationsDaniel L. Kenney, Eduardo E. Benarroch et al.Neurology, July 22, 2015